EASL 48th Annual Meeting April 24th - 28th 2013 The Netherlands, Amsterdam

Conference Reports for NATAP


EASL 48th Annual Meeting April 24th - 28th 2013 The Netherlands, Amsterdam

	HBV at EASL Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy - (06/11/13) 48 Weeks of Peginterferon Alfa-2a/Ribavirin Improves SVR24 and Decreases Relapse across HCV Genotype 2/3 Patient Subgroups Not Achieving a Rapid Virological Response: N-CORE Study - (05/11/13) 5-year Entecavir treatment in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics - (05/15/13) Liver Disease in HBV-HIV Coinfection- Significant Fibrosis is Present Despite HBV Suppression and Anti-Retroviral Therapy - (05/15/13) Virological Response Does Not Lower Liver Disease Progression Among Chronic Hepatitis B Cirrhotic Patients Treated with Long-Term Nucleo(t)ide-Analogue - (05/15/13) INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE REABSORPTION IN NAIVE CHB PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY - (05/15/13) HARPE Study: Prevalence of Renal Abnormalities in Chronic Hepatitis B Virus Infection - (05/15/13) FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RISISTENCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY - (05/15/13) Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study - (05/15/13) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/13/13) Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72 - (05/09/13) S-collate cohort 'real-life' study: efficacy and safety of peginterferon alfa-2a (40KD) in 1233 patients with chronic hepatitis B according to Asian and Caucasian race - (05/09/13) Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients - (05/08/13) Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma - (05/08/13) Tenofovir Disoproxil Fumarate in Chronic HBV Patients With Normal ALT Levels and High HBV DNA Levels, also titled: TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUS-INFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE - (05/08/13) Comparison of Serum HBsAg Declines During Tenofovir Disoproxil Fumarate (TDF) Treatment in Different Chronic Hepatitis B (CHB) Patient Populations - (05/08/13) HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBE-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HEPNET.GREECE COHORT STUDY - (05/08/13) ALT Flares During Treatment with Peginterferon Lambda-1a or Peginterferon Alfa in Patients With HBeAg-positive Chronic Hepatitis B Infection (CHB) - (05/08/13) IMPROVED HBsAg LOSS RATE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PROLONGED PEGINTERFERON α-2A COMBINED WITH NUCLEOS(T)IDE ANALOGUE - (05/08/13) Tenofovir Disoproxil Fumarate (TDF) Is Safe and Well Tolerated in Chronic Hepatitis B (CHB) Patients With Pre-Existing Mild Renal Impairment - (05/08/13)